• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Zydus Cadila get US FDA approval for Atazanavir capsules

expresspharmaJune 08, 2020

Tag: Zydus Cadila , Atazanavir Capsules , FDA

Zydus Cadila has received final approval from the USFDA to market Atazanavir Capsules in the strengths of 150 mg, 200 mg and 300 mg. Atanazavir, an antiretroviral drug, is used to treat infection of the human immunodeficiency virus (HIV).

It is used in combination with other antiretroviral drugs to treat HIV-1 infection. The drug will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.

The group now has 291 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.


Previous:Local API production in India for COVID-19 repurposed drugs may offer competitive advantage: GlobalData

Next:Anti-TNF therapies could treat patients with COVID-19-related ARDS

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Zydus Cadila get US FDA approval for Atazanavir capsules | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

Clindamycin Phosphate( FDA)

Clindamycin Phosphate( FDA)
Adriacin HCL (FDA)

Adriacin HCL (FDA)
Prednisolone (FDA /COS)

Prednisolone (FDA /COS)
9,9-Bis(4-amino-3-fluorophenyl) Fluorene (FFDA)

9,9-Bis(4-amino-3-fluorophenyl) Fluorene (FFDA)
Ivermectin (FDA)

Ivermectin (FDA)
Mitomycin ( FDA)

Mitomycin ( FDA)
Deltamine (FDA)

Deltamine (FDA)
Fully compliant FDA 21 CFR part 11 handheld raman spectrometer

Fully compliant FDA 21 CFR part 11 handheld raman spectrometer
Cyclosporin A (FDA)

Cyclosporin A (FDA)
Etoposide( FDA)

Etoposide( FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service